Lexicon Pharmaceuticals, Inc.
LXRXNASDAQHealthcare● Active
$1.91
+$0.01(+0.53%)
Market Cap$848414360
P/E Ratio—
52W High$2.53
52W Low$0.64
Lexicon Pharmaceuticals, Inc. (LXRX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LXRX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $49.80M | $31.08M | $1.20M | $0.14M | $0.30M |
| Cost of Revenue | $0.27M | $0.62M | $58.97M | $52.52M | $55.05M |
| Gross Profit | $49.53M | $30.46M | ($57.77M) | ($52.38M) | ($54.75M) |
| Gross Margin %(computed) | 99.45% | 98.02% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $61.12M | $84.48M | $58.89M | $52.82M | $55.05M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $98.44M | $227.58M | $113.98M | $48.38M | $32.34M |
| Operating Income | ($48.91M) | ($197.12M) | ($171.75M) | ($100.76M) | ($87.09M) |
| Operating Margin %(computed) | -98.21% | -634.20% | — | — | — |
| Interest Income | $6.91M | $12.29M | $7.73M | $1.60M | $0.13M |
| Interest Expense | $8.34M | $15.58M | $13.10M | $2.78M | $0.80M |
| Income Before Tax | ($50.34M) | ($200.40M) | ($177.12M) | ($101.94M) | ($87.76M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($50.34M) | ($200.40M) | ($177.12M) | ($101.94M) | ($87.76M) |
| Net Margin %(computed) | -101.08% | -644.78% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.61 |
| Wtd Avg Shares | 363.05M | 320.03M | 221.13M | 165.73M | 145.65M |
| EBITDA | ($48.29M) | ($184.29M) | ($169.76M) | ($100.03M) | ($86.80M) |
| EBITDA Margin %(computed) | -96.96% | -592.93% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Lexicon Pharmaceuticals, Inc. data
About Lexicon Pharmaceuticals, Inc. (LXRX) Income Statement
Lexicon Pharmaceuticals, Inc. (LXRX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, LXRX reported revenue of $0.05B, gross profit of $0.05B (gross margin 99.45%), and net income of ($0.05B) — a net profit margin of -101.08%.
Frequently asked questions
LXRX · 4 questionsLexicon Pharmaceuticals, Inc. (LXRX) reported revenue of $0.05B for 2025, up 60.2% year-over-year.
LXRX revenueLXRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08